# EDGAR Filing Document

**Accession Number:** 0001783036
**File Stem:** 0001213900-25-057281
**Filing Date:** 2025-6
**Character Count:** 29809
**Document Hash:** f2fa939da892d7543742fd971b8cd2a7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-057281.hdr.sgml**: 20250624

**ACCESSION NUMBER**: 0001213900-25-057281

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250624

**DATE AS OF CHANGE**: 20250624

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NLS Pharmaceutics Ltd.
- **CENTRAL INDEX KEY:** 0001783036
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** V8
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92065
- **FILM NUMBER:** 251069880

**BUSINESS ADDRESS:**
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **STATE:** V8
- **ZIP:** CH-6370
- **BUSINESS PHONE:** 41-41-618-80-00

**MAIL ADDRESS:**
- **STREET 1:** THE CIRCLE 6
- **STREET 2:** 8058
- **CITY:** ZURICH
- **STATE:** V8
- **ZIP:** CH-6370
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hafner Ronald
- **CENTRAL INDEX KEY:** 0002045580

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** C/O NLS PHARMACEUTICS LTD.
- **STREET 2:** THE CIRCLE 6
- **CITY:** ZURICH
- **STATE:** V8
- **ZIP:** 8058

## Ex-11

**Exhibit 11**

**PUT-CALL AGREEMENT**

Dated as of October 9, 2024

By and Among

Alpha Capital Anstalt

and

Ronald Hafner

THIS PUT-CALL AGREEMENT (the "<u>Agreement</u>") is entered into as of October 9, 2024, by and among the following parties (collectively, the "<u>Parties</u>", or, individually, a "<u>Party</u>"):

Alpha Capital Anstalt, ("<u>Alpha</u>"); and

Ronald Hafner ("<u>Purchaser</u>).

**Recitals**

WHEREAS, the Purchaser has or will purchase 37,783 common shares of NLS Pharmaceutics Ltd., a corporation incorporated under the laws of Switzerland (the "<u>Company</u>") (the "<u>Purchaser Common Stock</u>") for a purchase price of $150,000.00;

WHEREAS, pursuant to a separate agreement between the Company and the Purchaser, upon the occurrence of certain events, the Purchaser Common Stock may convert into shares of the Company's preferred stock (the "<u>Conversion</u>"), of which will be underlined by the Company's common shares (the "<u>Conversion Shares</u>"); and

WHEREAS, the Parties wish to enter into an agreement whereby following the Conversion, upon demand, for the purchase price of $150,000.00: (a) the Purchaser shall have the right to sell to Alpha the Conversion Shares; and (b) Alpha shall have the right to purchase from the Purchase the Conversion Shares.

**Agreement**

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants and conditions herein contained, and intending to be legally bound, the Parties hereby agree as follows:

**ARTICLE I**

**Purchaser's Put Option Provisions**

Section 1.01. <u>Grant of Put Option</u>

Subject to the terms of this Agreement, Alpha hereby voluntarily, irrevocably and exclusively grants Purchaser a put option to demand, at Purchaser's sole discretion, that Alpha purchase all but not less than all of the Conversion Shares from Purchaser at a price equal to $150,000.00 (the "<u>Put Option</u>"), at any time and using any lawful methodology, as directed by Purchaser. Purchaser hereby agrees to accept the Put Option. Purchaser shall initiate its Put Option rights under this Section 1.01 by delivery of written notice to both the Company and Alpha of the exercise of such rights under this Section 1.01 (the "<u>Put Notice</u>").

Section 1.02. <u>Closing</u>

Closing of the Put Option shall occur no later than ten (10) business days following the delivery of the Put Notice. All parties agree to proceed in good faith and with due diligence to close any such transaction, including prompt preparation and execution of those documents necessary to complete the transaction. At closing, the full purchase price shall be paid in full, in cash, by Alpha.

Section 1.03 Other Provisions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. If the Purchaser Common Stock is not converted into Conversion Shares by December 31, 2024, the Purchaser has the right to sell the Purchaser Common Stock at any time. The present Put-Call Option Agreement shall lapse.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. As long as neither the Call nor the Put option is exercised, voting rights attached to the Purchaser Common Stock and the Conversion Shares respectively, may be exercised by the Purchaser at his full discretion.

**ARTICLE III**

**The Company's Call Option Provisions**

Section 2.01. <u>Grant of Call Option</u>

Subject to the terms of this Agreement, Purchaser hereby voluntarily, irrevocably and exclusively grants to Alpha a call option to demand, at Alpha's sole discretion, that Purchaser sell all but not less than all of the Conversion Shares to Alpha at a purchase price equal to $150,000.00 (the "<u>Call Option</u>"), at any time and using any lawful methodology, as directed by Alpha. Alpha hereby agrees to accept the Put Option. Alpha shall initiate its Put Option rights under this Section 2.01 by delivery of written notice to both the Company and Purchaser of the exercise of such rights under this Section 2.01 (the "<u>Call Notice</u>").

Section 2.02. <u>Closing</u>

Closing of the Call Option shall occur no later than ten (10) business days following the delivery of the Call Notice. All parties agree to proceed in good faith and with due diligence to close any such transaction, including prompt preparation and execution of those documents necessary to complete the transaction. At closing, the purchase price shall be paid in full, in cash, by the Purchaser.

**ARTICLE III**

**Other**

Section 3.01. <u>Notices</u>

All notices, requests and other communications hereunder to a Party shall be in delivered electronically in writing and shall be deemed given on the date of email, in each case to such Party at its electronic mailing address (e-mail) number set forth below.

<u>If to Purchaser</u>:

Ronald Hafner

c/o NLS Pharmaceutics Ltd.

The Circle 6

8058 Zurich, Switzerland

with a copy to:

Wenger Vieli Ltd.

Dufourstrasse 56

P.O. Box 8034

Zurich, Switzerland

Attn: Pascal Honold, Esq.

Email: p.honold@wengervieli.ch

<u>If to Alpha</u>:

Alpha Capital Anstalt

Altenbach 8

9490 Vaduz

Principality of Liechtenstein

Email: info@alphacapital.li

with a copy to:

Grushko & Mittman, P.C.

1800 Rockaway Ave., Ste. 206

Hewlett, NY 11557

Email: ed@grushkomittman.com

Attn: Edward M. Grushko, Esq.

<u>If to Company</u>:

NLS Pharmaceutics Ltd.

The Circle 6

8058 Zurich

Switzerland

Attn: Alexander Zwyer, CEO

Email: az@nls-pharma.com

With a copy to:

Sullivan & Worcester LLP

1251 Avenue of the Americas

New York, NY 10020

Attn: Ron Ben-Bassat, Esq.

Email: rbenbassat@sullivanlaw.com

Section 3.02. <u>Entire Understanding; No Third-Party Beneficiaries</u>

This Agreement represents the entire understanding of the Parties with reference to the transactions contemplated hereby and this Agreement supersedes any and all other oral or written agreements heretofore made with respect to the subject matter hereof. Nothing in this Agreement, expressed or implied, is intended to confer upon any Person, other than the Parties, or their respective successors and permitted assigns, any rights, remedies, obligations or liabilities under or by reason of this Agreement.

Section 3.03. <u>Waiver; Amendment</u>

Any provision of this Agreement may be (a) waived by the Party benefited by the provision, or (b) amended or modified at any time, by an agreement in writing among the Parties approved or authorized and executed by each Party in the same manner as this Agreement.

Section 3.04. <u>Expenses</u>

Each Party will bear all expenses incurred by it in connection with this Agreement and the transactions contemplated hereby. In the event that any signature is delivered by e-mail delivery of a ".pdf" format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such ".pdf" signature page were an original thereof.

Section 3.05. <u>Counterparts</u>

This Agreement may be executed in two or more counterparts, each of which shall be deemed to constitute an original.

Section 3.06. <u>Governing Law</u>

This Agreement shall be governed by, and interpreted in accordance with, the laws of the State of New York applicable to contracts made and to be performed entirely within such State. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any action, suit or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party and each signatory hereto on behalf of the Company, hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof.

 

*[Signature page to follow]*

IN WITNESS WHEREOF, the Parties have executed this Agreement, in the case of the Company and Purchaser, by their duly authorized officers, as of the date first above stated.

---

| | |
|:---|:---|
| Alpha Capital Anstalt | Alpha Capital Anstalt |
| By: | /s/ Nicola Feuerstein |
| Name: | Nicola Feuerstein |
| Title: | Director |
| Ronald Hafner | Ronald Hafner |
| /s/ Ronald Hafner | /s/ Ronald Hafner |

---

## Ex-12

**Exhibit 12**

**Declaration of Assignment**

WHEREAS, the undersigned party, Alex Zwyer, Steinegg 1011, 9053 Teufen, herewith assigns and transfers to

Ronald Hafner, Weinbergstrasse 72, 8703 Erlenbach, Switzerland<br> (the "**Assignee**")

111'637 common stocks of NLS Pharmaceutics Ltd. a corporation under the laws of Switzerland (the "**Company**"), with a par value of CHF 0.03 each (as amended from time to time) and all rights connected therewith as of the date of this declaration.

This agreement shall be governed by and construed in accordance with the substantive laws of Switzerland, excluding the United Nations Convention on Contracts for the International Sale of Goods dated 11 April 1980 (CISG), as amended from time to time. All disputes arising out of or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment and termination, shall be resolved by the ordinary courts in Zurich 1, Switzerland.

---

| | |
|:---|:---|
| Teufen, February 7, 2025 | /s/ Alex Zwyer |
| Place, date | Assignor: Alex Zwyer |

---

Acceptance of such assignment is hereby confirmed:

---

| |
|:---|
| /s/ Ronald Hafner |
| Assignee: |
| Ronald Hafner |

---

## Ex-13

**Exhibit 13**

NLS Pharmaceutics AG

Board of Directors

The Circle 6

8058 Zürich

St. Niklausen, 21.02.2025

**Notification according to article 697 of the Swiss Code of Obligations ("CO")**

Dear Sirs

We herewith notify you that Magnetic Rock Investment AG, Langensandhöhe 15, 6005 St.Niklausen transferred all shares held in NLS Pharmaceutics AG to:

● Jürgen Bauer, Etzlibergstrasse 28, 8800 Thalwil (17'781 ordinary shares)

● Ronald Hafner, Weinbergstrasse 72, 8703 Erlenbach (17'782 ordinary shares)

● Peter Lennart Nils Ödman, Sunnenhalden 27, 8712 Stäfa (17'781 ordinary shares)

● Michael Albert Stein, Unter den Reben 5, 4312 Magden (17'781 ordinary shares)

We would like to thank you for taking note and ask you to adjust the share register accordingly.

Yours sincerely,

---

| | |
|:---|:---|
| /s/ Ronald Hafner | /s/ Cristoph Huber |
| Ronald Hafner | Christoph Huber |

---

## Ex-14

**Exhibit 14**

**Declaration of Assignment**

WHEREAS, the undersigned party, Patrick Hafner, Dornacherstr. 18, 4053 Basel, Switzerland, herewith assigns and transfers to

Ronald Hafner, Weinbergstrasse 72, 8703 Erlenbach, Switzerland<br> (the "**Assignee**")

250 common stocks of NLS Pharmaceutics Ltd. a corporation incorporated under the laws of Switzerland (the "**Company**"), with a par value of CHF 0.03 each (as amended from time to time) and all rights connected therewith as of the date of this declaration.

This agreement shall be governed by and construed in accordance with the substantive laws of Switzerland, excluding the United Nations Convention on Contracts for the International Sale of Goods dated 11 April 1980 (CISG), as amended from time to time. All disputes arising out of or in connection with the present Agreement, including disputes on its conclusion, binding effect, amendment and termination, shall be resolved by the ordinary courts in Zurich 1, Switzerland.

---

| | |
|:---|:---|
| Basel, May 22, 2025 | /s/ Patrick Hafner |
| Place, date | Assignor: Patrick Hafner |

---

Acceptance of such assignment is hereby confirmed:

---

| |
|:---|
| /s/ Ronald Hafner |
| Assignee:<br> Ronald Hafner |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**NLS Pharmaceutics Ltd.**

*(Name of Issuer)*

**Common Share, Par Value CHF 0.03 Per Share**

*(Title of Class of Securities)*

**H57830103**

*(CUSIP Number)*

**Ronald Hafner**<br>c/o NLS Pharmaceutics Ltd.<br>The Circle 6<br>Zurich V8 8058<br>41-44-512-2150

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**05/22/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **H57830103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ronald Hafner** | Name of reporting person<br>**Ronald Hafner** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**V8** | Citizenship or place of organization<br>**V8** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**557131.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**557131.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**557131.00** | Aggregate amount beneficially owned by each reporting person<br>**557131.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**13.2%** | Percent of class represented by amount in Row (11)<br>**13.2%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Percentage ownership is based on a total of 4,097,641 common shares, par value CHF 0.03 per share, or the Common Shares, outstanding as of June 20, 2025, as reported in the Issuer's Registration Statement on Form F-4/A, filed with the U.S. Securities and Exchange Commission on June 20, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Share, Par Value CHF 0.03 Per Share

**(b) Name of Issuer:**
NLS Pharmaceutics Ltd.

**(c) Address of Issuer's Principal Executive Offices:**
The Circle 6, Zurich, V8, 8058

**Item 4. Purpose of Transaction**

The information set forth in Items 3 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. The Reporting Person holds all securities of the Issuer for investment purposes only.

The Common Shares beneficially owned by the Reporting Person were purchased in a series of investment transactions since the initial public offering of the Issuer, including through the transactions described herein below, as well as acquisitions in the open market.

On October 9, 2024, the Issuer, entered into a securities purchase agreement, or the Equity Purchase Agreement, with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Equity Purchase Agreement, the Issuer agreed to issue and sell to the investors, in a private placement offering, (i) 806,452 Common Shares, and (ii) common share purchase warrants, or the Common Warrants, to purchase 806,452 Common Shares, at a combined purchase price of $3.97, for aggregate gross proceeds of $3.2 million. The Common Warrants have a term of five years and have an exercise price of $4.25 per share. Pursuant to the Equity Purchase Agreement, the Issuer agreed to grant the investors the right to participate, in the aggregate, in up to fifty percent (50%) of future offerings for one year following the closing of the offering. In addition, the Issuer agreed to not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. The transactions contemplated by the Equity Purchase Agreement closed on October 10, 2024. In connection with this Equity Purchase Agreement, the Reporting Person purchased 100,807 Common Shares and Common Warrants to purchase 100,807 Common Shares, all with his personal funds.

On October 9, 2024, the Issuer and certain existing warrant holders entered into warrant amendment agreements, or collectively, the Amendment, to amend those warrants issued by Company to such holders, collectively, to purchase up to 105,843 Common Shares issued to such holders, or the Existing Warrants. The Amendment amended the definition of "Fundamental Transaction" in Section 3(e) of the Existing Warrants. In consideration for the Amendment, the Issuer agreed to adjust the exercise price of the Common Warrants to CHF 0.80 and issued to the holders Pre-Funded Warrants to purchase up to 136,648 Common Shares, or the Pre-Funded Warrants. Each Pre-Funded Warrant is exercisable for one Common Share at an exercise price of CHF 0.80 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In connection with the Amendment, Existing Warrants to purchase 1,800 Common Shares were amended under the Amendment, and the Reporting Person received Pre-Funded Warrants to purchase 1,925 Common Shares.

On October 9, 2024, the Issuer entered into a securities purchase agreement, or the Debt Purchase Agreement, with an accredited investor, pursuant to which in exchange for the satisfaction of the Issuer's debt in the aggregate amount of $4.0 million held by the investor, the Issuer agreed to issue 806,452 newly designated convertible preferred shares, at a purchase price of $4.96 (rounded). The preferred shares contain a conversion price of $4.96 per share. The transactions contemplated by the Debt Purchase Agreement closed on October 10, 2024. Pursuant to the Debt Purchase Agreement, the Issuer agreed to grant the investor the right to purchase up to an additional $10.0 million worth of convertible preferred shares beginning six months after the closing and continuing for as long as the investor owns preferred shares. Additionally, pursuant to the Debt Purchase Agreement, the Issuer agreed to grant the investor the right to participate in up to fifty percent (50%) of future offerings of the Issuer's securities for one year following the closing. In addition, the Issuer agreed to not to enter into an equity line of credit or similar agreement, without the consent of the majority of the holders of the preferred shares. In connection with this Debt Purchase Agreement, the Reporting Person received 173,173 designated convertible preferred shares. The Reporting Person funded this transaction with his personal funds.

On October 9, 2024, the Reporting Person further entered into a Put-Call Agreement with an accredited investor, pursuant to which the accredited investor granted the Reporting Person a put option to demand at its sole discretion, and the Reporting Person granted the accredited investor a call option to demand at its sole discretion, that the accredited investor purchase an amount of 37,783 preferred shares converted from 37,783 Common Shares held by the Reporting Person in consideration for $150,000. On February 12, 2025, the Reporting Person and the accredited investor entered into a Declaration of Assignment agreement, pursuant to which the accredited investor shall exercise the aforesaid option as of the date of the Declaration of Assignment.

On February 7, 2025, the Reporting Person entered into a Declaration of Assignment agreement with Mr. Alexander Zwyer, the chief executive officer of the Issuer, pursuant to which in exchange for the satisfaction of a debt held by the Reporting Person, Mr. Zwyer agreed to transfer 111,637 Common Shares to the Reporting Person.

On February 21, 2025, Magnetic Rock Investment AG transferred 17,782 Common Shares at market value to the Reporting Person in exchange for the satisfaction of a debt held by the Reporting Person.

On May 22, 2025, the Reporting Person entered into a Declaration of Assignment agreement with Mr. Patrick Hafner, the Reporting Person's brother, whose holdings are separate from the Reporting Person, pursuant to which in exchange for a cash amount equal to the Common Shares aggregate market value, Mr. Patrick Hafner agreed to transfer 250 Common Shares to the Reporting Person.

The Reporting Person serves as the Chairman of the Board of Directors of the Issuer, or the Chairman. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of Schedule 13D. Except as otherwise described herein, the Reporting Person currently has no plan(s) or proposal(s) that relate to, or would result in, any of the events or transactions described in Item 4(a) through (j) of Schedule 13D, although the Reporting Person reserves the right, at any time and from time to time, to review or reconsider its position and/or change its purpose and/or formulate plans or proposals with respect thereto. The Reporting Person intends to review from time to time his investment in the Issuer and the Issuer's business affairs, financial position, performance and other investment considerations. The Reporting Person may from time to time engage in discussions with the Issuer, its directors and officers, other shareholders of the Issuer and other persons on matters that relate to the management, operations, business, assets, capitalization, financial condition, strategic plans, governance and the future of the Issuer and/or its subsidiaries. Based upon such review and discussions, as well as general economic, market and industry conditions and prospects and the Reporting Person's liquidity requirements and investment considerations, and subject to the limitations in the agreements described above, the Reporting Person may consider additional courses of action, which may include, in the future, formulating plans or proposals regarding the Issuer and/or its subsidiaries, including possible future plans or proposals concerning events or transactions of the kind described in Item 4(a) through (j) of Schedule 13D.

In his capacity as the Chairman, from time to time, the Reporting Person may receive share options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for non-employee directors. In connection with the foregoing, in November 2022, the Reporting Person was granted options to purchase 3,688 Common Shares of the Issuer.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person beneficially owns 557,131 Common Shares, representing approximately 15.0% of the outstanding Common Shares.

**(b)**
The Reporting Person holds sole voting and dispositive power over 557,131 Common Shares of the Issuer which includes 3,176 Common Shares of the Issuer issuable upon the exercise of stock options, or the Options, awarded by the Issuer to the Reporting Person for the Reporting Person's service as a member of the board of directors of the Issuer and held directly by the Reporting Person and vested and exercisable within 60 days of the date of event that requires the filing of this Statement on Schedule 13D. This number also includes warrants to purchase 113,861 Common Shares and Pre-Funded Warrants to purchase 1,925 Common Shares held directly by the Reporting Person. The warrants are exercisable as follows: (i) warrants to purchase 13,054 Common Shares are vested and exercisable, or will be vested and exercisable, within 60 days of the date of event that requires the filing of this Statement on Schedule 13D, (ii) Common Warrants to purchase 100,807 Common Shares are only exercisable to the extent that after giving effect or immediately prior to such exercise the holders thereof, their affiliates and any person who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-1 under the Exchange Act, no more than 9.99% of the outstanding Common Shares, and (iii) Pre-Funded Warrants to purchase 1,925 Common Shares are only exercisable to the extent that after giving effect or immediately prior to such exercise the holders thereof, their affiliates and any person who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-1 under the Exchange Act, no more than 4.99% of the outstanding Common Shares. As a result of this restriction, the number of Common Shares that may be issued upon exercise of the warrants by the above holder may change depending upon changes in the outstanding Common Shares.s

**(c)**
The Reporting Persons has not effected any transactions in the Common Shares in the past 60 days, except as set forth in Item 3 and Item 4, which is incorporated by reference herein.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

The information set forth in Item 3, Item 4 and Item 5 of this Schedule 13D is incorporated by reference in its entirety into this Item 6.

As the Chairman of the Issuer, the Reporting Person may have the ability to affect and influence control of the Issuer. From time to time, the Reporting Person may receive share options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for non-employee directors. In connection with the foregoing, in November 2022, the Reporting Person was granted options to purchase 3,688 Common Shares of the Issuer, of which options to purchase 3,176 Common Shares are vested and exercisable within 60 days of the date of event that requires the filing of this Statement on Schedule 13D.

In connection with the Agreement of Merger and Plan of Reorganization, dated November 4, 2024, between Kadimastem Ltd., an Israeli publicly traded company limited by shares, the Issuer and NLS Pharmaceuticals (Israel) Ltd., an Israeli company and a wholly owned subsidiary of the Issuer, the Reporting Person entered into a Support Agreement under which the Reporting Person has agreed, among other things, to vote its Common Shares, and any other voting securities the Reporting Person might hold, in favor of the approval of (i) the issuance of Common Shares equal to the required number of Common Shares to serve as the merger consideration, and (ii) an ordinary capital increase under Swiss law, excluding the subscription rights of the existing holders of Common Shares, for the purpose of making available the required number of Common Shares to serve as the merger consideration.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ronald Hafner

**Signature:** /s/ Ronald Hafner

**Name/Title:** Ronald Hafner, Chairman of the Board of Directors

**Date:** 06/24/2025